Legal Spotlight: Replimune Faces Investor Scrutiny After FDA Decision

A Complete Response Letter Triggers Class Action Investigation

Replimune Group, Inc. (NASDAQ: REPL) recently landed in the legal spotlight after receiving a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application for RP1 in combination with nivolumab, targeting advanced melanoma. The FDA expressed disagreement over the sufficiency of data supporting the application, halting the company’s progress on this potential treatment.

Following this news, Pomerantz LLP—a law firm renowned for securities and class action litigation—announced its investigation into possible securities fraud and business practices by Replimune and specific officers or directors. Investors are invited to join the class action, with details provided by the firm for further inquiry.

Stock Price Rebounds, but Uncertainty Remains

Shares of Replimune experienced a significant drop on April 13, 2026, closing at $1.70—down 64.29% following the FDA rejection. However, as of 11:15 AM today, the stock price has risen to $4.94, as market participants assess both legal and operational risks.

Legal and Regulatory Outlook: Major Questions for Shareholders

Pomerantz LLP’s investigation zeroes in on the transparency and potential missteps in Replimune’s communications and business practices. While no formal allegations have been made yet, the law firm’s involvement underscores growing concern among shareholders about possible breaches of fiduciary duty. This class action could impact future disclosures, executive accountability, and ultimately, investor confidence.

Key Takeaway: Monitoring Legal Developments May Be Crucial

With the stock recovering from an earlier freefall and legal action underway, investors are left weighing the impact of regulatory decisions, potential litigation, and any new company updates. For those holding REPL or tracking legal risk in biotech stocks, staying attuned to further disclosures, including the outcome of the Pomerantz investigation, will be essential.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI